VIS 624

Drug Profile

VIS 624

Alternative Names: VIS624

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Visterra
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 29 Jun 2017 Visterra plans to initiate proof of efficacy studies in 2019 (Visterra pipeline, June 2017)
  • 15 Jan 2017 Preclinical trials in Multiple myeloma in USA (Parenteral) (Visterra pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top